KMKevin McGrath

Kevin McGrath

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kevin McGrath has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EUS-guided liver biopsy: the optimal technique?

    by Jonathan Wilen, Kevin McGrath

    Liver biopsy remains the gold standard for diagnosis of parenchymal liver disease. For decades, percutaneous liver biopsy (PLB) has been performed at bedside, based on percussion of the right hepatic lobe. Considered the gold standard, PLB now frequently employs image guidance, most commonly utilizing pre-biopsy ultrasound marking or real-time guidance. Transjugular liver biopsy (TJLB), performed by interventional radiologists, is ideal for patients with ascites, coagulopathy or obesity. In almost all cases, TJLB also samples the right hepatic lobe via the right hepatic vein given the anatomic access advantage. Article published online: 23 February 2023 © 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Mo1294 UNIQUE DELETERIOUS GENE MUTATIONS EXCLUSIVELY ASSOCIATED WITH PREMALIGNANT AND MALIGNANT IPMN

    by Asif Khalid, Kevin McGrath, Georgios I. Papachristou, Kenneth Fasanella, Jennifer Chennat, Aatur Singhi, Adam Slivka, Maureen Lyons, Chris Drescher, James Hirmas, et al.

  • Sa1380 - A Decrease in T-Stage from Eus Guided Diagnosis to Time of Resection is Predictive of Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma

    by Rohit Das, Natalie Seiser, Kevin McGrath, Randall Brand, Jennifer S. Chennat, Kenneth Fasanella, Asif Khalid, Georgios I. Papachristou, Adam Slivka, Nathan Bahary, et al.

  • Risk of Progression after a Diagnosis of Low Grade Dysplasia Varies Between Hospitals for Patients Under Surveillance for Barrett's Esophagus

    by Maulin Shah, Christopher Deitrick, Randall Brand, Jennifer S. Chennat, Kenneth Fasanella, Kevin McGrath, Jon M. Davison

  • Next-Generation Sequencing Improves the Detection of Malignant Biliary Strictures: A Prospective Study of 62 Bile Duct Brushings/Biopsies

    by Aatur Singhi, Herbert J. Zeh, Marina N. Nikiforova, Jennifer S. Chennat, Asif Khalid, Georgios I. Papachristou, Mordechai Rabinovitz, Savreet Sarkaria, Kevin McGrath, Melissa E. Hogg, et al.

  • Open Access

    Management of incidental pancreatic cysts: which guidelines?

    by Kevin McGrath

    Medicine is not a perfect science. That is no truer than in the evaluation and management of the asymptomatic pancreatic cyst. Ever more common, these cystic lesions frustrate gastroenterologists, surgeons and patients alike. Existing consensus statements and societal guidelines have been based upon expert opinion and little evidence, frequently leaving physicians who care for these patients with more questions than answers. The recent American Gastroenterological Association (AGA) guidelines, which many view as controversial, have continued to stir this pot. From a historical perspective, pancreatic cyst guidelines have continued to evolve over the last decade. The first guidelines (American Society for Gastrointestinal Endoscopy, 2005) recommended endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of all cysts for cyst fluid analysis and cytology [1]. The Sendai guidelines (International Association of Pancreatology, 2006) specifically addressed Intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, and called for more selective use of EUS based on cyst size and presence of worrisome features [2]. The updated Fukuoka guidelines (International Association of Pancreatology, 2012) similarly recommended the presence of a worrisome feature for evaluation by EUS; cyst size became less of a concern. Worrisome features include cyst size size ≥ 30 mm, enhanced thickened cyst walls, non-enhanced mural nodules, main pancreatic duct (MPD) size 5 to 9 mm, abrupt change in MPD caliber with distal glandular atrophy, and lymphadenopathy. Criteria for surgical referral according to the Fukuoka guidelines are any high-risk stigmata which include obstructive jaundice in the setting of a pancreatic head cyst, presence of a mural nodule/solid component, MPD ≥ 10 mm or cytology suspicious or positive for malignancy [3]. The current AGA guidelines (2015) deal with management of asymptomatic cysts, without regard to cyst type. They recommend the presence of 2 high-risk stigmata (cyst size size ≥ 30 mm, dilated MPD, solid component) before an EUS examination be performed. For surgical referral, the AGA guidelines require malignant cytology on EUS-FNA or at least 2 high-risk features (cyst size size ≥ 30 mm, dilated MPD, solid component)[4]. Thus, with time and knowledge, guidelines have become more conservative with the recognition that the malignant risk of an asymptomatic cyst is very low. Accordingly, magnetic resonance imaging (MRI) for surveillance is increasingly recommended. In this edition of Endoscopy International Open, 2 articles pour more gas on the fire. Lee et al.’s retrospective 2-part study evaluates and compares the operating characteristics of the AGA and Fukuoka guidelines for detection of and surgical referral for malignant pancreatic cysts [5]. An EUS database was used to determine appropriateness for EUS referral of a MRI-detected asymptomatic cyst (n = 143) based on criteria for such according to the 2 sets of guidelines. For EUS detection of a high-risk cyst (HGD or carcinoma), the Fukuoka guidelines were more sensitive (33.3 % vs 16.7 %) but less specific (65.4 % vs 94.4 %) compared to the AGA guidelines. This is no surprise given the guidelines’ criteria for EUS referral. Twenty three cysts were referred for surgery based on EUS findings; 7 were malignant or harbored HGD. Using definitive cytology and/or surgical histology, based on AGA guidelines, 5 of the 7 (71.4 %) high-risk cysts did not meet criteria for EUS referral, where 3 of 7 (42.9 %) did not meet criteria by the Fukuoka guidelines. The second part of the study analyzed the guidelines for referral to surgical resection utilizing a pathology database of resected asymptomatic cysts (n = 152) that had undergone MRI and EUS. Based on criteria for surgical referral, the performance characteristics did not differ statistically between the guidelines; 30.9 % and 36.2 % of patients would have been referred by the AGA and Fukuoka guidelines, respectively. For high-risk cysts based on surgical pathology (n = 17), 5 of 17 (29.4 %) did not meet surgical criteria by AGA guidelines; 3 of these 17 (17.6 %) did not meet criteria by Fukuoka guidelines. According to both sets of guidelines, 75 % of the surgical resections in this study were considered unnecessary. Certainly, if AGA guidelines are followed, there will be a decrease in EUS procedures and surgical resections (at the risk of missing advanced neoplasia). However, it is somewhat unfair to apply these current guidelines to a surgical practice that spanned from 1995 to 2013, which was the time period for the surgical portion of the study. Given our knowledge deficits at the time, I suspect many cyst resections from 1995 to 2005 would have been considered unnecessary by today’s standards, regardless of either guideline. The Ge et al. study retrospectively applied the AGA guidelines to a large multicenter cohort of pancreatic cysts (n = 300) which underwent surgical resection from 2004 – 2014 [6]. All patients had undergone preoperative EUS. The AGA guidelines would have recommended surgery in 40 % of these patients; of them, 37 % where ultimately found to have advanced neoplasia, defined by the presence of cancer or HGD. Sixty percent of the cohort would have avoided surgery, with cancer being missed in 5 %. On the surface, it appears that the AGA guidelines may have performed fairly well in the Ge et al. study, correctly recommending surveillance in 95 % of patients. However, if we further dissect the results, 54 total patients in the study were found to have malignant pancreatic cysts. Nine of 54 patients had missed cancers; these had no evidence of concerning cytology and fewer than 2 high-risk features. Of the remaining 45 patients with malignant cysts, 24 patients were recommended for surgery solely on the basis of concerning cytology. Fifteen of these 24 patients had only one high-risk feature, and 9 had no...


  • Prevalence of esophageal neoplasia in short-segment versus long-segment Barrett’s esophagus

    by Joy Chang, Kenneth Fasanella, Jennifer Chennat, Jon Davison, Kevin McGrath


  • Mo1515 Role of Pancreatic Cyst Fluid GNAS and KRAS Mutations in the Diagnosis of IPMN

    by Asif Khalid, Aatur D. Singhi, Geeta Mantha, Tracey A. Hoteck, Kenneth E. Fasanella, Jennifer S. Chennat, Kevin Mcgrath, Georgios I. Papachristou, Marina N. Nikiforova


  • Tu1114 Assessment of Gastric Cardia to Monitor the Response to Endoscopic Therapy in Patients With Esophageal Dysplasia and Adenocarcinoma

    by Kenneth E. Fasanella, Rajan K. Bista, Kevin D. Staton, Randall Brand, Kevin McGrath, Yang Liu